Smith & Nephew PLC (SNN) Stock AnalysisSNNSmith & Nephew PLC

Smith & Nephew plc is a portfolio medical technology company. The Company is focused on the repair, regeneration, and replacement of soft and hard tissue. The Company's segments include Orthopaedics, which includes a range of hip, knee and shoulder implants used to replace diseased, damaged or worn joints, robotics-assisted enabling technologies that empower surgeons, and trauma products used to stabilize severe fractures and correct bone deformities; Sports Medicine & ENT businesses offer advanced products and instruments used to repair or remove soft tissue, and Advanced Wound Management provides a comprehensive set of products to meet broad and complex clinical needs, and to help healthcare professionals reduce the human and economic consequences of wounds. The Company also owns Integrity Orthopaedics, which is an early stage commercial developer of Tendon Seam, an innovative and disruptive biomechanical RCR system. It operates in the Healthcare sector (ORTHOPEDIC, PROSTHETIC, AND SURGICAL APPLIANCES AN industry).

Smith & Nephew is not a good buy right now. The current price is $28.97, and the RSI is at 33.68, indicating oversold conditions. However, the company has seen a 21.49% decline over the past year and is facing significant challenges in the U.S. Orthopaedics market, with analysts downgrading their outlook and price targets. The main risk is the hedge funds selling, which has increased by 225.80% over the last quarter, indicating a lack of confidence among institutional investors.

4 analysts cover SNN: 3 rate it Buy, 1 Hold and 0 Sell. The average price target is 35.75.